BioPulse retweeted
$LXEO large unmet need here ir.lexeotx.com/static-files/…
$LXEO Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and 44% mean reduction in premature ventricular contractions at latest assessment
LX2020 generally well tolerated across 10 participants with no clinically significant complement activation
U.S. Food and Drug Administration open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020
Cash, cash equivalents and investments of $219.1 million expected to provide operational runway into 2028
Company to host webcast today at 8:00 AM ET
BioPulse retweeted
$AQST - Anaphylm will probably be approved before the PDUFA date of March 16, 2027. I believe Anaphylm will be approved before the biggest allergy conference of the year. It’s the AAAAI annual meeting on February 19-22, 2027. This would potentially be “the coming out party for Anaphylm” as Sherry Korczynski-Chief Commercial Officer puts it.
ARS Pharmaceuticals got approval 142 days after resubmitting the NDA for Neffy. If this holds true or close enough then Anaphylm should be approved around the second week of February (7-12). That is 1 week prior to Quad AI (AAAAI) annual meeting.
If Approved, Anaphylm will be the biggest event at the meeting.
annualmeeting.aaaai.org/atte…
BioPulse retweeted
This is such a fucking disgrace. Insider trading of a grand scale.
Just A Coincidence? Both Trump And Ro Khanna Sold Nvidia Stock Before CEO Scandal Erupted zerohedge.com/political/just…
BioPulse retweeted
$SVRA
-HC Wainwright initiates Savara coverage at Buy
-Highlights MOLBREEVI, a once-daily inhaled granulocyte-macrophage colony-stimulating factor, that could become the first FDA-approved therapy for autoimmune pulmonary alveolar proteinosis
-Sets $10 target
investing.com/news/analyst-r…
BioPulse retweeted
HC Wainwright & Co. assumes coverage of Savara at Buy, sets price target at $10
$SVRA
BioPulse retweeted
$PFE dropped Metsera alleged oral GLP1. Also dropped GIP peptide ..
Now no talk about single amylin trial data.
Amylin and GLP1 data “ just for PK and safety “
Essentially the Metsera platform that Pfizer M&A head Andrew Baun talked about trickled to one semaglutide efficacy GLP1. That might be given monthly .. we don’t know how popular any monthly will be given irreversibility of clinical effects .. bad or good.
And how much Pfizer will generate from 12 shorts per year ?
$AMGN has its issues with monthly MariTide not the least is viscous 2.5 ML solution that pt has to inject.
After all obesity not as crowded as $JNJ CEO believes ?
Waw …since when $PFE needs help for funding its clinical trials. ? And giving out some milestones and loyalties 😂
Why not cutting the dividend?
Bourla likely does not have confidence in this GLP1 asset ?
You do not compete in the biggest market against the trillion $ leader $LLY with a subpar asset that is barely competitive with $NVO sema ?
Trying to save a few billions on acquisition.. and then u get stuck with billions in trials cost..
BioPulse retweeted
Replying to @Biotechnerd1
$SVRA if you look at it
No treatment available. Monopoly
No safety issues compared to placebo
Excellent data Ph3 (maybe 1 lesser secondary)
PDUFA pushed forward, not rejected
Orphan status
If ✅ by FDA, EU UK follow
Commercial USA by Q1 '27
SOC instantly
BioPulse retweeted
$PRAX
Raymond James is very bullish- 945 PT.
Raymond James reiterated $PRAX Strong Buy-$945 and said--We continue to view Praxis as one of the most compelling setups in SMID biotech, with the next few months offering multiple opportunities to unlock the value of what we believe could become two multi-billion-dollar CNS franchises.
[DRUG JAZZ RAPP SAGE UCBJY ESAIY OVID XENE]
Our deep dive (link) into relu's mechanism, breadth of preclinical evidence, and EMERALD's heterogeneity risk leaves us constructive on both the probability of Ph3 success and the magnitude of its commercial opportunity.
Separately, our due diligence (link) on ulixa's clinical and regulatory package, including its statistical considerations and regulatory precedent, underpins our high conviction in approval at the January 29 PDUFA.
We are encouraged by management's commercial readiness, with relu's commercial organization fully hired and ulixa's field-force buildout progressing ahead of potential launches.
Taken together, we believe Praxis is approaching a transformational stretch, with a catalyst-rich outlook, substantial commercial upside, and a balance sheet that positions the company to execute from a position of strength.
BioPulse retweeted
Chop chop BP , no time to waste
My take on BP moves:
$jnj : $cogt , $dftx , $ptgx
$lly: $abvx , $mane , $celc , $prax
$mrk: $lqda, $rvmd
$sny: $pcvx , $insm
$abbv: $xene , $prax , $abvx , $vktx
$azn: $cgon , $rytm, $insm, $abvx
$nvs: $cytk , $srrk , $vrdn
$Rhhby: $iron , $vera, $cccc
$pfe: $celc , $cogt , $arct
$bms: $elvn , $cldx
$gsk: $cldx, $amlx , $cccc
$nvo: $gpcr, $ewtx , $rytm
BioPulse retweeted
$INO…
BioPulse retweeted
$NRIX Piper PT $35 $1.1B in cash (end 3Q), NRIX
enterprise value is~$1B in value. current PT is unchanged since did not have
SAR448272 in our valuation model. There's valuation support from NRIX's bexobrutideg
(partnered with Roche) which is in Ph3 trials in CLL and potential advancement of Ph2
development in autoimmune indications. Bexobrutideg offers potential differentiation
compared to other BTK degraders in development.
$NRIX to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition globenewswire.com/news-relea…
BioPulse retweeted
Replying to @PositiveTopline @BlaseBio
$MLYS buying opportunity??
CV drugs are always slow to ramp.
Entresto had a very slow start (<$20M for first 3 quarters after launch) and eventually made $7.8B in peak sales
BioPulse retweeted
$NRIX Baird fundamental enthusiasm has been 100% on bexobrutideg and we believe buying into the weakness of the STAT6 trade unwind will reward patient investors as Roche navigates development across a range of B-cell malignancies as well as I&I indications.
BioPulse retweeted
$NRIX disclosed that $SNY will end its Phase 1 study of oral STAT6 degrader SAR448272 and stop the initiative, removing prospective commercial milestones and royalty revenues from the candidate. Additional Sanofi-partnered efforts remain active for milestone payouts, while Nurix preserves $1.1 billion in reserves to fund operational runway into H2 2029.
$KTTA $BIVI $CAPR $KPTI $RMTI $PMN $ALZN $ATHE $JAGX $CYCN
For more biotech updates, join us on 🔗 BioPharmCatalyst 📰 Articles section
BioPulse retweeted
$NRIX I think we see multiple analyst defenses tomorrow. Looking for 20+. A discontinuation of a phase 1 study of one of multiple drugs actually saves money 😂
BioPulse retweeted
long $NRIX at 17, if you were buying this for the STAT6 program and not the NX5948 degrader then idk what to tell you - massive over reaction imo
$NRIX Nurix Therapeutics: Sanofi Discontinues Phase 1 Trial of STAT6 Degrader SAR448272, Terminates Development Program
⠀
• Discontinuation: Sanofi ends the Phase 1 trial and terminates the SAR448272 development program.
• Financial Impact: Nurix no longer expects future milestone payments or royalties from SAR448272.
• Cash Runway: Unchanged, with $1.1B in cash and investments expected to fund operations into H2 2029.
• Pipeline: Roche-partnered bexobrutideg remains in Phase 3, while NX-1607 and Gilead-partnered GS-6791 continue clinical development.



























